HRP20170638T1 - MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI - Google Patents
MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI Download PDFInfo
- Publication number
- HRP20170638T1 HRP20170638T1 HRP20170638TT HRP20170638T HRP20170638T1 HR P20170638 T1 HRP20170638 T1 HR P20170638T1 HR P20170638T T HRP20170638T T HR P20170638TT HR P20170638 T HRP20170638 T HR P20170638T HR P20170638 T1 HRP20170638 T1 HR P20170638T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- compound
- substituted
- phenyl
- chloro
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 102100023421 Nuclear receptor ROR-gamma Human genes 0.000 title 1
- 108091008773 RAR-related orphan receptors γ Proteins 0.000 title 1
- 230000001363 autoimmune Effects 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- IQXNFWSDMOQEKD-SFHVURJKSA-N n-[5-chloro-3-[[(3s)-4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]-6-methylpyridine-3-carboxamide Chemical compound C([C@@H](N(CC1)C(=O)C2CCCC2)C)N1CC(C=1C)=CC(Cl)=CC=1NC(=O)C1=CC=C(C)N=C1 IQXNFWSDMOQEKD-SFHVURJKSA-N 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 2
- AJCOAFFYLRVSDI-DJPFJPOOSA-N C[C@H]1C[C@H](C1)C(=O)N1CCN(Cc2cc(Cl)cc(NC(=O)c3ccc(C)nc3)c2C)C[C@@H]1C Chemical compound C[C@H]1C[C@H](C1)C(=O)N1CCN(Cc2cc(Cl)cc(NC(=O)c3ccc(C)nc3)c2C)C[C@@H]1C AJCOAFFYLRVSDI-DJPFJPOOSA-N 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- DMYWSDLHUTVLIF-JGCRXCKMSA-N n-[5-fluoro-2-methyl-3-[[(3s)-3-methyl-4-(3-methylcyclobutanecarbonyl)piperazin-1-yl]methyl]phenyl]-6-methylpyridine-3-carboxamide Chemical compound C1C(C)CC1C(=O)N1[C@@H](C)CN(CC=2C(=C(NC(=O)C=3C=NC(C)=CC=3)C=C(F)C=2)C)CC1 DMYWSDLHUTVLIF-JGCRXCKMSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- VYEPBICDVLUWKG-INIZCTEOSA-N 3-cyano-n-[3-[[(3s)-4-(3,3-difluorocyclobutanecarbonyl)-3-methylpiperazin-1-yl]methyl]-5-fluoro-2-methylphenyl]benzamide Chemical compound C([C@@H](N(CC1)C(=O)C2CC(F)(F)C2)C)N1CC(C=1C)=CC(F)=CC=1NC(=O)C1=CC=CC(C#N)=C1 VYEPBICDVLUWKG-INIZCTEOSA-N 0.000 claims 1
- AQGBWBMWWNRWNU-SFHVURJKSA-N 3-cyano-n-[3-[[(3s)-4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl]methyl]-5-fluoro-2-methylphenyl]benzamide Chemical compound C([C@@H](N(CC1)C(=O)C2CCCC2)C)N1CC(C=1C)=CC(F)=CC=1NC(=O)C1=CC=CC(C#N)=C1 AQGBWBMWWNRWNU-SFHVURJKSA-N 0.000 claims 1
- AJCOAFFYLRVSDI-MDKPJZGXSA-N C[C@H]1C[C@@H](C1)C(=O)N1CCN(Cc2cc(Cl)cc(NC(=O)c3ccc(C)nc3)c2C)C[C@@H]1C Chemical compound C[C@H]1C[C@@H](C1)C(=O)N1CCN(Cc2cc(Cl)cc(NC(=O)c3ccc(C)nc3)c2C)C[C@@H]1C AJCOAFFYLRVSDI-MDKPJZGXSA-N 0.000 claims 1
- KJBFHFGUGFHFHH-BXWFABGCSA-N C[C@H]1C[C@@H](C1)C(=O)N1CCN(Cc2cc(Cl)cc(NC(=O)c3cnc(C)nc3)c2C)C[C@@H]1C Chemical compound C[C@H]1C[C@@H](C1)C(=O)N1CCN(Cc2cc(Cl)cc(NC(=O)c3cnc(C)nc3)c2C)C[C@@H]1C KJBFHFGUGFHFHH-BXWFABGCSA-N 0.000 claims 1
- KJBFHFGUGFHFHH-TXPKVOOTSA-N C[C@H]1C[C@H](C1)C(=O)N1CCN(Cc2cc(Cl)cc(NC(=O)c3cnc(C)nc3)c2C)C[C@@H]1C Chemical compound C[C@H]1C[C@H](C1)C(=O)N1CCN(Cc2cc(Cl)cc(NC(=O)c3cnc(C)nc3)c2C)C[C@@H]1C KJBFHFGUGFHFHH-TXPKVOOTSA-N 0.000 claims 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims 1
- ZGUUFGJXZFLEFM-INIZCTEOSA-N n-[3-[[(3s)-4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl]methyl]-5-fluoro-2-methylphenyl]-2-methylpyrimidine-5-carboxamide Chemical compound C([C@@H](N(CC1)C(=O)C2CCCC2)C)N1CC(C=1C)=CC(F)=CC=1NC(=O)C1=CN=C(C)N=C1 ZGUUFGJXZFLEFM-INIZCTEOSA-N 0.000 claims 1
- IPMMIRCXAWHKPW-KRWDZBQOSA-N n-[5-chloro-3-[[(3s)-4-(2-cyclopropylacetyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]-6-methylpyridine-3-carboxamide Chemical compound C([C@@H](N(CC1)C(=O)CC2CC2)C)N1CC(C=1C)=CC(Cl)=CC=1NC(=O)C1=CC=C(C)N=C1 IPMMIRCXAWHKPW-KRWDZBQOSA-N 0.000 claims 1
- HAXBJJXPLDXDIL-INIZCTEOSA-N n-[5-chloro-3-[[(3s)-4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl]methyl]-2-methylphenyl]-2-methylpyrimidine-5-carboxamide Chemical compound C([C@@H](N(CC1)C(=O)C2CCCC2)C)N1CC(C=1C)=CC(Cl)=CC=1NC(=O)C1=CN=C(C)N=C1 HAXBJJXPLDXDIL-INIZCTEOSA-N 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (21)
1. Spoj Formule I ili njegova farmaceutski prihvatljiva sol
[image]
naznačen time što:
R1 je:
– C1-C6 alkil;
– metil, supstituiran s i) C3-C5 cikloalkilom; ii) fenoksi; ili iii) fenilom i drugim supstituentom, kojeg se bira iz skupine koju čine: metil, halogen i metoksi;
– etil, supstituiran s i) fenilom, gdje navedeni fenil može biti supstituiran s halogenom ili metoksi, ili ii) heteroarilom;
– benzil, gdje fenilna skupina u navedenom benzilu može biti supstituirana s halogenom, metoksi ili SO2CH2CH3;
– C2 alkenil, koji može biti supstituiran s jednim F i jednim fenilom;
– C3-C7 cikloalkil, gdje navedeni cikloalkil može biti supstituiran s jednim ili dva supstituenta, koje se bira iz skupine koju čine fenil, metil i F; ili navedeni cikloalkil može biti kondenziran s fenilnim prstenom;
– heterocikloalkil, koji može biti supstituiran s jednim ili dva C1-C3 alkil;
– heteroaril, koji može biti supstituiran s jednim do dva supstituenta, koje se bira iz skupine koju čine: C1-C3 alkil, C1-C3 alkoksi i CF3; i
– fenil, supstituiran s jednim do tri supstituenta, koje se bira iz skupine koju čine:
i) halogen;
ii) CN;
iii) C1-C3 alkil, koji može biti supstituiran s jednim do tri F;
iv) C1-C3 alkoksi;
v) (CH2)nNRaRb;
vi) C(O)CH3; i
vii) CH2OCH3;
R2 je halogen ili C1-C3 alkil;
R3 je halogen ili metil;
R4 je H ili metil;
R5 je C1-C3 alkil;
R6 je C1-C3 alkil;
R7 se bira iz skupine koju čine:
– C1-C7 alkil, koji može biti supstituiran s jednim ili više supstituenata, koje se bira iz skupine koju čine halogen, C3-C5 cikloalkil i CF3;
– C3-C7 cikloalkil, koji može biti supstituiran s jednim ili dva supstituenta, koje se bira iz skupine koju čine F, CH2F, CHF2, metil i metoksi,
svaki k je 0 ili 1; svaki p je 0 ili 1; svaki n je 0, 1 ili 2;
svaki Ra je H ili C1-C3 alkil; svaki Rb je H ili C1-C3 alkil.
2. Spoj ili sol u skladu s patentnim zahtjevom 1, naznačen time što je R1 heteroaril, supstituiran s C1-C3 alkilom.
3. Spoj ili sol u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je R1 piridinil, supstituiran s metilom.
4. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je R2 metil.
5. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što je k 1, a R3 je Cl ili F.
6. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je R4 H.
7. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je R5 metil.
8. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je p 0.
9. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je R7 C3-C6 cikloalkil, koji može biti supstituiran s jednim ili dva F ili metil.
10. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je R7 ciklobutil, supstituiran s metil ili dva F.
11. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je R7 ciklopentil.
12. Spoj ili sol u skladu s patentnim zahtjevom 1, naznačen time što se spoj bira između:
(S)-N-(3-((4-(ciklopentankarbonil)-3-metilpiperazin-1-il)metil)-5-fluor-2-metilfenil)-2-metilpirimidin-5-karboksamida;
(S)-N-(5-klor-3-((4-(ciklopentankarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6-metilnikotinamida;
(S)-3-cijano-N-(3-((4-(3,3-difluorciklobutankarbonil)-3-metilpiperazin-1-il)metil)-5-fluor-2-metilfenil)benzamida;
(S)-N-(5-klor-3-((4-(2-ciklopropilacetil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6-metilnikotinamida;
N-(5-fluor-2-metil-3-(((S)-3-metil-4-((cis)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-6-metilnikotinamida;
N-(5-fluor-2-metil-3-(((S)-3-metil-4-((trans)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-6-metilnikotinamida;
N-(5-klor-2-metil-3-(((S)-3-metil-4-((trans)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-6-metilnikotinamida;
N-(5-klor-2-metil-3-(((S)-3-metil-4-((cis)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-6-metilnikotinamida;
N-(5-klor-2-metil-3-(((S)-3-metil-4-((cis)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-2-metilpirimidin-5-karboksamida;
N-(5-klor-2-metil-3-(((S)-3-metil-4-((trans)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-2-metilpirimidin-5-karboksamida; i
(S)-N-(5-klor-3-((4-(ciklopentankarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-2-metilpirimidin-5-karboksamida.
13. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je (S)-3-cijano-N-(3-((4-(ciklopentankarbonil)-3-metilpiperazin-1-il)metil)-5-fluor-2-metilfenil)benzamid; ili njegova farmaceutski prihvatljiva sol.
14. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je (S)-N-(5-klor-3-((4-(ciklopentankarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6-metilnikotinamid; ili njegova farmaceutski prihvatljiva sol.
15. Spoj naznačen time što je (S)-N-(5-klor-3-((4-(ciklopentankarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6-metilnikotinamid, Formule:
[image]
.
16. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je N-(5-klor-2-metil-3-(((S)-3-metil-4-((cis)-3-metilciklobutankarbonil)piperazin-1-il)metil)fenil)-6-metilnikotinamid; ili njegova farmaceutski prihvatljiva sol.
17. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 16, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u terapiji.
18. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 16, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju psorijaze.
19. (S)-N-(5-Klor-3-((4-(ciklopentankarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6-metilnikotinamid, naznačen time što je namijenjen upotrebi u liječenju psorijaze.
20. Farmaceutski pripravak, naznačen time što sadrži spoj Formule I u skladu s bilo kojim od patentnih zahtjeva 1 do 16, ili njegovu farmaceutski prihvatljivu sol, kao i farmaceutski prihvatljivu podlogu ili pomoćnu tvar.
21. Farmaceutski pripravak, naznačen time što sadrži (S)-N-(5-klor-3-((4-(ciklopentankarbonil)-3-metilpiperazin-1-il)metil)-2-metilfenil)-6-metilnikotinamid, kao i farmaceutski prihvatljivu podlogu ili pomoćnu tvar.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012001636 | 2012-12-06 | ||
CN2013000182 | 2013-02-25 | ||
CN2013000803 | 2013-07-01 | ||
EP13799318.4A EP2928885B1 (en) | 2012-12-06 | 2013-12-05 | Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases |
PCT/EP2013/075594 WO2014086894A1 (en) | 2012-12-06 | 2013-12-05 | Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20170638T1 true HRP20170638T1 (hr) | 2017-06-30 |
Family
ID=49709687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170638TT HRP20170638T1 (hr) | 2012-12-06 | 2017-04-24 | MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI |
Country Status (33)
Country | Link |
---|---|
US (1) | US10005731B2 (hr) |
EP (2) | EP2928885B1 (hr) |
JP (1) | JP6279605B2 (hr) |
KR (1) | KR20150092244A (hr) |
CN (1) | CN105121430B (hr) |
AR (1) | AR093818A1 (hr) |
AU (1) | AU2013354109B2 (hr) |
BR (1) | BR112015013137B1 (hr) |
CA (1) | CA2894016C (hr) |
CL (1) | CL2015001557A1 (hr) |
CR (1) | CR20150302A (hr) |
CY (1) | CY1118932T1 (hr) |
DK (1) | DK2928885T3 (hr) |
EA (1) | EA026437B1 (hr) |
ES (1) | ES2626390T3 (hr) |
HK (1) | HK1214814A1 (hr) |
HR (1) | HRP20170638T1 (hr) |
HU (1) | HUE033212T2 (hr) |
IL (1) | IL239082A0 (hr) |
LT (1) | LT2928885T (hr) |
ME (1) | ME02696B (hr) |
MX (1) | MX2015007180A (hr) |
PE (1) | PE20151144A1 (hr) |
PH (1) | PH12015501244A1 (hr) |
PL (1) | PL2928885T3 (hr) |
PT (1) | PT2928885T (hr) |
RS (1) | RS55875B1 (hr) |
SG (1) | SG11201504200TA (hr) |
SI (1) | SI2928885T1 (hr) |
TW (1) | TW201427959A (hr) |
UY (1) | UY35174A (hr) |
WO (1) | WO2014086894A1 (hr) |
ZA (1) | ZA201503666B (hr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9745297B2 (en) | 2013-07-30 | 2017-08-29 | Boehringer Ingelheim International Gmbh | Compounds as modulators of RORC |
SG11201606080SA (en) | 2014-02-03 | 2016-08-30 | Vitae Pharmaceuticals Inc | Dihydropyrrolopyridine inhibitors of ror-gamma |
EP3148985A4 (en) | 2014-05-28 | 2018-01-17 | GlaxoSmithKline Intellectual Property Development Limited | Novel compounds |
CN106536489B (zh) * | 2014-05-28 | 2020-02-07 | 葛兰素史密斯克莱知识产权发展有限公司 | 类视黄醇相关孤儿受体γ调节剂及其用途 |
WO2015180614A1 (en) * | 2014-05-28 | 2015-12-03 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
CN104292208A (zh) * | 2014-09-09 | 2015-01-21 | 上海师范大学 | 7-苯基-6,8-二氧杂螺[3.5]壬烷-2-羧酸及其制备方法 |
MA40759A (fr) * | 2014-09-26 | 2017-08-01 | Pfizer | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation |
HUE042335T2 (hu) | 2014-10-14 | 2019-06-28 | Vitae Pharmaceuticals Inc | ROR-gamma dihidropirrolopiridin inhibitorai |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
TW201625588A (zh) * | 2014-11-05 | 2016-07-16 | 第一三共股份有限公司 | 環狀胺衍生物 |
WO2016120849A1 (en) * | 2015-01-30 | 2016-08-04 | Pfizer Inc. | Methoxy-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof |
EP3331876B1 (en) | 2015-08-05 | 2020-10-07 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
EP3377482B1 (en) * | 2015-11-20 | 2021-05-12 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
UA123330C2 (uk) * | 2016-07-13 | 2021-03-17 | Лео Фарма А/С | Гетероароматичні модулятори ретинол-зв'язаного орфанного рецептора гамма |
CN109134476B (zh) * | 2017-06-15 | 2021-03-19 | 复旦大学 | 桥环哌嗪类衍生物或其盐及其制备方法和用途 |
TW201908280A (zh) * | 2017-07-18 | 2019-03-01 | 瑞士商隆薩有限公司 | 製備5-氟-2-甲基-3-硝基苯甲酸及其甲酯的方法 |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
MX2020000887A (es) | 2017-07-24 | 2020-07-22 | Vitae Pharmaceuticals Llc | Inhibidores de ror?. |
CN108752185A (zh) * | 2018-07-17 | 2018-11-06 | 成都道合尔医药技术有限公司 | 一种1-氟-环戊甲酸的合成方法 |
CN109438423A (zh) * | 2018-09-12 | 2019-03-08 | 通化师范学院 | 一种肺癌靶向化合物azd-3759的合成工艺的新方法 |
CN110862319A (zh) * | 2019-12-04 | 2020-03-06 | 深圳振强生物技术有限公司 | 奥扎格雷杂质的制备方法 |
WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7790726B2 (en) | 2005-08-16 | 2010-09-07 | Chemocentryx, Inc. | Monocyclic and bicyclic compounds and methods of use |
US20070208000A1 (en) * | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
US7825120B2 (en) * | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
US7989455B2 (en) * | 2005-12-19 | 2011-08-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
WO2012028100A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
WO2012027965A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
WO2012100734A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
WO2012100732A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof |
EP2511263A1 (en) * | 2011-04-14 | 2012-10-17 | Phenex Pharmaceuticals AG | Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
WO2012145254A2 (en) | 2011-04-16 | 2012-10-26 | Board Of Regents, The University Of Texas System | Methods of using inhibitors of rorϒt to treat disease |
MX2013012542A (es) | 2011-04-28 | 2013-11-20 | Japan Tobacco Inc | Compuestos de amida y aplicacion farmaceutica para el mismo. |
WO2012158784A2 (en) | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulators of the nuclear hormone receptor ror |
CA2847563A1 (en) | 2011-09-09 | 2013-03-14 | New York University | Amido compounds as ror.gamma.t modulators and uses thereof |
GB201116641D0 (en) | 2011-09-27 | 2011-11-09 | Glaxo Group Ltd | Novel compounds |
GB201207406D0 (en) | 2012-04-27 | 2012-06-13 | Glaxo Group Ltd | Novel compounds |
UY34765A (es) | 2012-04-27 | 2013-11-29 | Glaxo Group Ltd | Compuestos novedosos. |
WO2013171729A2 (en) | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
WO2015061686A2 (en) | 2013-10-25 | 2015-04-30 | St. Jude Children's Research Hospital, Inc. | Retinoid x receptor-gamma agonists and retinoid x receptor-alpha antagonists for treatment of cancer |
US20160257664A1 (en) | 2013-10-25 | 2016-09-08 | Glaxosmithkline Llc | Novel compounds |
CN106536489B (zh) | 2014-05-28 | 2020-02-07 | 葛兰素史密斯克莱知识产权发展有限公司 | 类视黄醇相关孤儿受体γ调节剂及其用途 |
WO2015180614A1 (en) | 2014-05-28 | 2015-12-03 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
EP3148985A4 (en) | 2014-05-28 | 2018-01-17 | GlaxoSmithKline Intellectual Property Development Limited | Novel compounds |
-
2013
- 2013-12-05 EA EA201591059A patent/EA026437B1/ru not_active IP Right Cessation
- 2013-12-05 PL PL13799318T patent/PL2928885T3/pl unknown
- 2013-12-05 DK DK13799318.4T patent/DK2928885T3/en active
- 2013-12-05 US US14/649,585 patent/US10005731B2/en active Active
- 2013-12-05 BR BR112015013137-9A patent/BR112015013137B1/pt active IP Right Grant
- 2013-12-05 PT PT137993184T patent/PT2928885T/pt unknown
- 2013-12-05 KR KR1020157017633A patent/KR20150092244A/ko not_active Application Discontinuation
- 2013-12-05 LT LTEP13799318.4T patent/LT2928885T/lt unknown
- 2013-12-05 WO PCT/EP2013/075594 patent/WO2014086894A1/en active Application Filing
- 2013-12-05 AU AU2013354109A patent/AU2013354109B2/en not_active Ceased
- 2013-12-05 RS RS20170372A patent/RS55875B1/sr unknown
- 2013-12-05 JP JP2015546002A patent/JP6279605B2/ja active Active
- 2013-12-05 SI SI201330650A patent/SI2928885T1/sl unknown
- 2013-12-05 UY UY0001035174A patent/UY35174A/es unknown
- 2013-12-05 EP EP13799318.4A patent/EP2928885B1/en active Active
- 2013-12-05 AR ARP130104518A patent/AR093818A1/es unknown
- 2013-12-05 EP EP17157475.9A patent/EP3219711A1/en not_active Withdrawn
- 2013-12-05 MX MX2015007180A patent/MX2015007180A/es unknown
- 2013-12-05 TW TW102144579A patent/TW201427959A/zh unknown
- 2013-12-05 SG SG11201504200TA patent/SG11201504200TA/en unknown
- 2013-12-05 CN CN201380070619.3A patent/CN105121430B/zh active Active
- 2013-12-05 ME MEP-2017-117A patent/ME02696B/me unknown
- 2013-12-05 CA CA2894016A patent/CA2894016C/en active Active
- 2013-12-05 ES ES13799318.4T patent/ES2626390T3/es active Active
- 2013-12-05 PE PE2015000712A patent/PE20151144A1/es not_active Application Discontinuation
- 2013-12-05 HU HUE13799318A patent/HUE033212T2/hu unknown
-
2015
- 2015-05-22 ZA ZA2015/03666A patent/ZA201503666B/en unknown
- 2015-05-28 IL IL239082A patent/IL239082A0/en unknown
- 2015-06-02 PH PH12015501244A patent/PH12015501244A1/en unknown
- 2015-06-05 CL CL2015001557A patent/CL2015001557A1/es unknown
- 2015-06-08 CR CR20150302A patent/CR20150302A/es unknown
-
2016
- 2016-03-09 HK HK16102705.4A patent/HK1214814A1/zh not_active IP Right Cessation
-
2017
- 2017-04-24 HR HRP20170638TT patent/HRP20170638T1/hr unknown
- 2017-06-02 CY CY20171100587T patent/CY1118932T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170638T1 (hr) | MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI | |
HRP20200341T1 (hr) | Bromodomenski (bet) inhibitori | |
JP2013510122A5 (hr) | ||
JP2016501250A5 (hr) | ||
PE20170705A1 (es) | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion) | |
NZ603594A (en) | Certain amino-pyrimidines, compositions thereof, and methods for their use | |
JP2014511892A5 (hr) | ||
NZ627750A (en) | Carbamate compounds and of making and using same | |
HRP20161103T1 (hr) | Kemijski spojevi | |
PE20110285A1 (es) | Derivados de sulfonamidofenil propionamida como ligandos del receptor vaniloide del subtipo 1 | |
RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
PE20140836A1 (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide | |
EA201591675A1 (ru) | Замещенные 7-азабициклы и их применение в качестве модуляторов рецепторов орексина | |
RU2015133450A (ru) | Соединения имидазопиридина и их применение | |
JP2014511891A5 (hr) | ||
RU2001125899A (ru) | Фенильные и пиридинильные производные | |
JP2014507455A5 (hr) | ||
AR049110A1 (es) | Compuestos terapeuticos: piridina como andamiaje estructural | |
RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
HRP20171515T1 (hr) | Spojevi fenoksietilpiperidina | |
RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
JP2013509392A5 (hr) | ||
RU2014101464A (ru) | Циклопропил-конденсированные-1,3-тиазепины в качестве ингибиторов васе 1 и(или) васе 2 | |
AR062299A1 (es) | Derivados de bencimidazol | |
RU2017145930A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) |